The short version of PPARδ agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
=== Differential diagnosis === Other conditions that can cause bluish skin include argyria, sulfhemoglobinemia, heart failure, amiodarone-induced bluish skin pigmentation and acrodermatitis enteropathica.
, where Y is the weak hypercharge, which suppresses in a natural way the dimension 5 operators for the proton decay; or SU(5) in Split SUSY, where the symmetry is broken in the Standard Model at very high scales, with the Higgs mass parameter appearing finely-tuned in the low-energy effective theory. Among the many things, this theory predicts very high values for proton decay. SUSY SU(5) can be extended to include supergravity or extra dimensions. SUGRA SU(5) is a supersymmetric Grand Unified Theory based on the SU(5) gauge group within the framework of supergravity (SUGRA). Proton lifetime predictions have been computed in SUSY SU(5) from 5 dimensions (5D) models; and in string theory variants using D6-branes and orientifolds. As a final consideration, while Supersymmetry addresses many interesting theoretical issues, its prediction of the mass of the lightest supersymmetric particles at the TeV scale has been severely matched by the LHC results. Proton decay lifetime predictions are summarized in the following table. By comparing these predictions with the sensitivities expected from future experiments, it becomes clear that experiments will never be able to rule out the entire vast range of possible models. However, they will cover the bulk of the predicted lifetimes, offering both a strong discovery potential if GUT models are realized in nature and a remarkable capacity to constrain GUT model building.
A dosage of 1 mg/day oral estradiol is considered to be roughly equivalent to 25 or 50 μg/day transdermal estradiol and a dosage of 2 mg/day oral estradiol is considered to be equivalent to 50 or 100 μg/day transdermal estradiol depending on the source. Estradiol patches delivering a daily dosage of 0.05 mg (50 μg) achieve mean estradiol and estrone levels of 30 to 65 pg/mL and 40 to 45 pg/mL, respectively, while a daily dosage of 0.1 mg (100 μg) attains respective mean levels of 50 to 90 pg/mL and 30 to 65 pg/mL of estradiol and estrone. In general, Climara-type estradiol transdermal patches have an approximate 1:1 ratio of estradiol delivered in μg/day relative to circulating estradiol concentration in pg/mL. In other words, a 100 μg/day Climara estradiol patch may be expected to produce circulating estradiol levels of around 100 pg/mL. Transdermal estradiol patches produce an estradiol to estrone ratio of about 1:1. Following removal of an estradiol patch, circulating estradiol levels decrease to baseline within 24 hours. Typical dosages of estradiol patches are intended to provide the minimum amount of estrogen replacement necessary for the effective alleviation of menopausal symptoms, and for this reason, they achieve relatively low levels of estradiol.
On September 11, 2013, a large human chain united from north to south the territory of Catalonia in what was called the "Catalan Way towards Independence" and three months later the parties advocating the "consultation" agreed on the question and the date of the consultation, set for November 9, 2014. In January 2014, the parliament of Catalonia passed a motion requesting the Congress of Deputies to cede the competence to hold the referendum, but on April 8 the request was rejected by the plenary by an overwhelming majority. As for the political crisis, the coming to power of the People's Party did not improve citizens' perception of politics. In November 2012 the barometer of the CIS indicated that the percentage of people fairly or very satisfied with the functioning of democracy in Spain was less than 30% when ten years earlier, also governing the Popular Party – but in a period of strong economic growth – it was close to 60%. Likewise, many of the political institutions suffered a sharp fall in the valuation of public opinion such as political parties, the government, the Congress of Deputies, trade unions and business organizations, all of them below the score of 3 (on a scale of 0 to 10), according to the CIS barometer of 2013, and from which the monarchy was not spared valued with a 3.68.
The NO can then contribute to two suggested pathways. Under typical conditions, nitric oxide (NO) interacts non-covalently with the heme and copper (Cu) subunits of CCO, competing with oxygen molecules and inhibiting cellular respiration, leading to reduced production of adenosine triphosphate (ATP). Low energy light can revise the mitochondrial inhibition of cellular respiration by photodissociating of NO from CCO, and thereby increasing ATP synthesis. The second pathway proposes that released nitric oxide (NO) will boost Cytochrome c Oxidase (CCO) activity, as an enzyme nitrite reductase. This mechanism includes the transfer of electrons to oxygen molecules, resulting in the production of water and reactive oxygen species (ROS). The ROS then activates enzymes necessary for producing vital cellular components like nucleic acids and proteins. LED therapy may also increase ROS, which may activate transcription factors that manage genes important for cell growth, cytokine production, and making growth factors for cell repair and proliferation.
Sources: en.wikipedia.org
=== 1928–1999 === In 1928, June Hobbs and a nurse opened Lake Wales' first hospital; it had nine beds and was in a two-story apartment. About one year later it closed. In 1929, Lake Wales, Highland Park and Mountain Lake raised $80,000 to build a 25-bed hospital. Lake Wales Hospital opened on March 12, 1930. Additional bedrooms were added in 1948 and 1956, increasing the number of beds to 60. In 1965, a new 110-bed hospital was built. Nine years later the third floor opened, increasing the number of beds to 154, and the original hospital became a medical office building. In 1985, construction workers began the construction of the Deeley A. Hunt Building, a 120-bed nursing home attached to the hospital. In 1993, Lake Wales Hospital merged with its nursing home and was renamed Lake Wales Medical Centers. Also in 1993, the hospital became part of Mid Florida Medical Services. In late November 1999, the Winter Haven Hospital Board of Trustees voted unanimously on expansion and renovation of Lake Wales Medical Center. They also approved the demolition of the former hospital.
=== Electrical and optical properties === Because honey contains electrolytes, in the form of acids and minerals, it exhibits varying degrees of electrical conductivity. Measurements of the electrical conductivity are used to determine the quality of honey in terms of ash content. The effect honey has on light is useful for determining the type and quality. Variations in its water content alter its refractive index. Water content can easily be measured with a refractometer. Typically, the refractive index for honey ranges from 1.504 at 13% water content to 1.474 at 25%. Honey also has an effect on polarized light, in that it rotates the polarization plane. The fructose gives a negative rotation, while the glucose gives a positive one. The overall rotation can be used to measure the ratio of the mixture. Honey is generally pale yellow and dark brown in color, but other colors can occur, depending on the sugar source. Bee colonies that forage on Kudzu (Pueraria montana var. lobata) flowers, for example, produce honey that varies in color from red to purple.
=== Fertilization === Depending on the species, spermatozoa can fertilize ova externally or internally. In external fertilization, the spermatozoa fertilize the ova directly, outside of the female's sexual organs. Female fish, for example, spawn ova into their aquatic environment, where they are fertilized by the semen of the male fish. Internal fertilization occurs inside the female's sexual organs after a male inseminates a female through copulation. Most vertebrates, including amphibians, reptiles, birds and monotreme mammals, are inseminated through the cloaca. Marsupials and placental mammals are inseminated through the vagina. In macropods, semen coagulates and forms a mating plug in the vagina after copulation.
=== Chemical descriptor based === In this approach, descriptors quantifying various electronic, geometric, or steric properties of a molecule are computed and used to develop a QSAR. This approach is different from the fragment (or group contribution) approach in that the descriptors are computed for the system as whole rather than from the properties of individual fragments. This approach is different from the 3D-QSAR approach in that the descriptors are computed from scalar quantities (e.g., energies, geometric parameters) rather than from 3D fields. An example of this approach is the QSARs developed for olefin polymerization by half sandwich compounds.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.